N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT
| 中文名称 | N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT |
|---|---|
| 中文同义词 | 化合物 T11038;二丁酰-CGMP 钠盐 |
| 英文名称 | N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT |
| 英文同义词 | dibutyryl cyclic 3',5'-guanosine monophosphate, sodium;N2,2μ-O-Dibutyrylguanosine 3μ,5μ-cyclic monophosphate hydrate sodium salt;N2,2μ-O-Dibutyrylguanosine 3μ,5μ-cyclic monophosphate dihydrate sodium salt;N,2'-O-Dibutyrylguanosine 3',5'-phosphoric acid;N2,2'-O-Dibutyryl cGMP;Dibutyryl-Cyclic GMP (sodium salt);n2,2’-o-dibutyrylguanosine-3’,5’-cyclicmonophosphate(dbcgmp),sodiumsalt;N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT |
| CAS号 | 51116-00-8 |
| 分子式 | C18H23N5NaO9P |
| 分子量 | 507.37 |
| EINECS号 | 2569922 |
| 相关类别 | Biochemicals and Reagents;Nucleosides, Nucleotides, Oligonucleotides;Nucleotide Analogs;Cyclic Nucleotide Metabolism;Cyclic Nucleotides and AnalogsSerine/Threonine Kinase Biology;G Proteins and Cyclic Nucleotides;Protein Kinase G (PKG);Serine/Threonine Kinase Activators |
| Mol文件 | 51116-00-8.mol |
| 结构式 |  |
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 性质
| 储存条件 | −20°C |
|---|---|
| 溶解度 | H2O:50 mg/mL |
| 形态 | 粉末 |
| 颜色 | 米白色 |
cGMP-dependent protein kinase (PKG);
ATP-sensitive K
+
channels
Dibutyryl-cGMP is able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels.
When cells are co-incubated with Dibutyryl-cGMP (100 μM) stress fibre formation is prevented and cells acquired a stellate morphology in cerebellar astrocytes.
In cells treated with Dibutyryl-cGMP (100 μM, 2 h) the particulate fraction is nearly devoid of RhoA protein. Dibutyryl-cGMP prevents RhoA-membrane association.
Using the scratchwound model, the size of the wound is significantly smaller in cells treated with Dibutyryl-cGMP after the wound indicating that dbcGMP accelerates wound closure.
Dibutyryl-cGMP (50-200 μg/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. Maximal antinociceptive effect of DbcGMP is at 1 h after administration and last for plus 2 h.
| Animal Model: | Male Wistar rats (180- 250 g) injection with Prostaglandin E2 (PGE2) |
| Dosage: | 50 μg/paw, 75 μg/paw, 100 μg/paw and 200 μg/paw |
| Administration: | Subcutaneous injection |
| Result: | Antagonized the hyperalgesic effect of PGE2 (2 μg/paw), in a dose-dependent manner. |
安全信息
| WGK Germany | 3 |
|---|---|
| F | 10-21 |
| 提供商 | 语言 |
|---|---|
|
英文
|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-130354 | Dibutyryl-cGMP sodium | 1 mg | 1590元 | |
| 2024/01/25 | HY-130354 | N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT Dibutyryl-cGMP sodium | 51116-00-8 | 5mg | 3500元 |